Worldwide Clinical Trials

FEBRUARY 21, 2024

During clinical development, new chemical entities (NCEs) require an absorption, metabolism, and excretion (AME) study. Regardless of the formulation, the entire dose must be administered to each subject, and the dosing containers must be checked for residual radioactivity.

Clinical Trials 200

Clinical Trials Clinical Trials Pharmacy Trials 200

Pharmaceutical Technology

FEBRUARY 26, 2023

The idea behind these treatments relies on altering the gut microbiome by designing therapeutics that contain bacteria derived from donated stool samples. Previously, Takeda had licensed the two Finch treatments FIN-524 and FIN-525 for their development in IBD.

Bacteria 278

Bacteria Trials Research Medicine 278

Druggist

SEPTEMBER 7, 2020

All of the non-prescription sleeping pills available in the UK contain sedative antihistamines. Over the counter sleeping pills UK: active ingredients All products available over the counter ‘for sleeping’ contain sedative antihistamines as the main active ingredient. Many factors can cause insomnia.

Containment 94

Containment Pharmacy Production Licensing 94

pharmaphorum

SEPTEMBER 29, 2021

The 10 startups – all from the US – will now embark on a four-week programme of assessment, training and development to ensure their technologies are ready for widespread deployment in the Amazon Web Services (AWS) cloud. The finalists are: AIVA , a startup that has developed a voice operating system for patient care.

FDA Approval 138

FDA Approval Pharmacy Development Containment 138

pharmaphorum

NOVEMBER 28, 2021

billion takeover of Sativex’ developer GW Pharma earlier this year. The drug is – an oral spray containing cannabinoids THC and CBD which is already licensed and sold by other companies in some markets for neuropathic pain, spasticity, overactive bladder, and other symptoms of multiple sclerosis.

Trials 136

Trials Drugs Clinical Trials Clinical Trials 136

pharmaphorum

NOVEMBER 1, 2021

Scemblix (asciminib) was one of a clutch of high risk, high reward drug candidates for a range of diseases that Novartis chief executive Vas Narasimhan said last year were flying under-the-radar of industry watchers, but could potentially develop into blockbusters.

Drugs 115

Drugs FDA Approval Trials Containment 115

The Pharma Data

MARCH 30, 2021

Expands Novartis Oncology radioligand pipeline with exclusive worldwide rights to develop and commercialize therapeutic applications for a library of FAP assets including FAPI-46 and FAPI-74. Novartis Oncology continues to reimagine cancer care through development of robust radioligand therapy portfolio. Disclaimer.

Protein 52

Protein Licensing Licensing Containment 52

The Pharma Data

MAY 7, 2021

population in just a few months, the BLA submission is an important cornerstone of achieving long-term herd immunity and containing COVID-19 in the future,” said Ugur Sahin, M.D., The Pfizer-BioNTech COVID-19 Vaccine, which is based on BioNTech proprietary mRNA technology, was developed by both BioNTech and Pfizer.

Licensing 52

Licensing Licensing Vaccination Vaccine 52

The Pharma Data

DECEMBER 12, 2020

Chief Executive Officer, Alexion , said: “For nearly 30 years Alexion has worked to develop and deliver transformative medicines to patients around the world with rare and devastating diseases. More recently, AstraZeneca has increased its efforts in immunology research and the development of medicines for immune-mediated diseases.

Development 75

Development Regulation Medicine Containment 75

The Pharma Data

NOVEMBER 4, 2020

(TSX: CTX) (OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house research & development (“R&D”) and manufacturing capabilities, today announced that it has entered into an exclusive agreement with Juyou-Biotechnology Co.

Licensing 40

Licensing Licensing Dermatology Production 40

The Pharma Data

DECEMBER 13, 2020

The FDA also recommended that Gamida Cell generate additional manufacturing-related data prior to requesting a pre-Biologics License Application (BLA) meeting. GDA-201 is in Phase 1 development through an investigator-sponsored study in patients with refractory non-Hodgkin lymphoma and multiple myeloma. About Omidubicel. About GDA-201.

Licensing 52

Licensing Licensing Clinical Trials Clinical Trials 52

Pharmaceutical Technology

FEBRUARY 16, 2023

The document contains detailed information on the suppliers and their product offerings, alongside contact details to aid your purchasing or hiring decision.

Engineer 130

Engineer Manufacturing Containment Production 130

The Pharma Data

AUGUST 17, 2020

Under the agreement, Bristol Myers Squibb will become responsible for the development and any subsequent commercialization of DF6002 and its related products worldwide, including strategic decisions, regulatory responsibilities, funding, and manufacturing. About Bristol Myers Squibb.

Licensing 52

Licensing Licensing Development Production 52

Druggist

FEBRUARY 24, 2021

Certain factors may contribute to the development of haemorrhoids, including (NICE, 2016): . Maintaining a good diet (high in fibre) and drinking plenty of fluids is the main recommendations to minimise the episodes of constipation and possible development of piles. When possible, painkillers containing codeine should be avoided.

Containment 96

Containment Pharmacy Production Sales 96

pharmaphorum

AUGUST 16, 2020

The European Commission has placed its first advance order for a coronavirus vaccine, snapping up 300 million doses of AstraZeneca’s ChAdOx1 candidate developed by the University of Oxford, with an option on another 100 million. The EU says its advance purchase order will finance part of the upfront costs of developing the vaccine.

Vaccination 111

Vaccination Vaccine Immune Response Trials 111

Druggist

JULY 22, 2020

All products listed above are licensed as pharmacy only medicines – ‘P’ products. The active ingredients contained in Night Nurse product include: dextromethorphan hydrobromide paracetamol promethazine hydrochloride Night Nurse is licensed for symptomatic management of cold and flu symptoms at night.

Nurses 52

Nurses Pharmacy Containment Licensing 52

Druggist

SEPTEMBER 15, 2020

Zovirax cream, marketed as Zovirax Cold Sore Cream, contains 5% of aciclovir. Zovirax cream for cold sores is licensed for the treatment of infections caused by Herpes simplex virus presented on lips or face in children and adults. Generic Zovirax cream for cold sores As previously mentioned, Zovirax cream contains 5% of aciclovir.

Containment 98

Containment Pharmacy Sales Drugs 98

FDA Law Blog

JUNE 3, 2021

A summary of these new state law developments is included below. Under the 2019 law, the price increase report had to contain, among other things, aggregate research and development costs, factors that led to the WAC increase, and the role of each factor’s impact on the cost.

Development 52

Development Drugs Manufacturing Pharmacy 52

The Pharma Data

DECEMBER 23, 2020

Agreement leverages Aurobindo’s existing development, commercial and manufacturing infrastructure. Commenting on the development, Mr. N. This vaccine has immense potential in eliminating shedding, and hence containing, the spread of the pandemic.” . HYDERABAD, India , Dec.

Vaccination 52

Vaccination Vaccine Development Manufacturing 52

Druggist

JANUARY 9, 2021

Smaller packs of paracetamol (contain 16 tablets or capsules) are available in all supermarkets and pharmacies for patient self-selection. There are plenty of paracetamol brands, most of which contain a standard adult dose of 500mg of paracetamol per tablet. Each Nurofen Meltlet contains 200mg of ibuprofen. Paracetamol.

Containment 98

Containment Pharmacy Drugs Production 98

The Pharma Data

DECEMBER 14, 2020

15, 2020 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that it entered into an exclusive licensing agreement with Oncocyte Corporation (NYSE American: OCX) to bring DetermaRx , a risk stratification test for early stage lung cancer patients, to China. 1 Kratz et al.,

Licensing 52

Licensing Licensing Marketing Gene Expression 52

The Pharma Data

DECEMBER 13, 2020

Under the collaboration, Genentech will assume development of RLY-1971 with the potential to expand into multiple combination studies including with Genentech’s investigational inhibitor of KRAS G12C, GDC-6036. “RLY-1971 RLY-1971 is a potent small molecule inhibitor of Src homology region 2 domain-containing phosphatase-2 (SHP2).

Licensing 40

Licensing Licensing Clinical Trials Clinical Trials 40

pharmaphorum

JANUARY 3, 2023

SPK-9001 is a novel, investigation vector containing a bio-engineered adeno-associated virus (AAV) capsid (protein shell) and a high-activity human coagulation FIX gene. The clinical trial participants will be evaluated as part of a long-term study over 15 years.

Gene Therapy 98

Gene Therapy Gene Medicine Trials 98

The Pharma Data

JANUARY 13, 2021

. Psychedelic Pharmaceutical Scientist and Clinical Pharmacologist Robert Barrow Appointed as Chief Development Officer. Mr. Barrow has over a decade of experience leading drug development programs aimed at identifying and testing novel treatments in a wide range of disease conditions under FDA and EMA.

Clinical Trials 52

Clinical Trials Clinical Trials Development Trials 52

Pfizer

JULY 26, 2022

The Pfizer-BioNTech COVID-19 Vaccine, BNT162b2, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines.

Vaccination 111

Vaccination Vaccine Protein Immune Response 111

pharmaphorum

DECEMBER 4, 2020

That means it targets both the primary mutation in this form of NSCLC and the resistance mechanism at the same time, according to J&J, which has previously said it plans to expand use of the drug to “all EGFR-containing tumours”, challenging Tagrisso and other TKIs like AZ’s older Iressa (gefitinib) and Roche’s Tarceva (erlotinib).

FDA Approval 93

FDA Approval Sales Antibody Drugs 93

pharmaphorum

JANUARY 20, 2022

The Swiss subsidiary of Glenmark Pharmaceuticals and Lotus International have signed a licensing agreement whereby Glenmark will handle the manufacture and supply of Ryaltris and Lotus will take charge of commercialising the drug, subject to approval. with allergic rhinitis.

Allergies 72

Allergies Marketing Production Manufacturing 72

Druggist

APRIL 6, 2021

LACRI-LUBE® Eye ointment (also marketed as Refresh Night Time® Eye ointment) is a pharmacy-only , preservative-free eye ointment licensed to lubricate and protect the eye associated with different eye conditions, for example, inflammation of the cornea of the eye, decreased corneal sensitivity, corneal erosions and eye surgery. . £5.90.

Pharmacy 93

Pharmacy Containment Sales Production 93

The Pharma Data

NOVEMBER 30, 2020

The lead candidate, HTL0022562, has advanced through preclinical development demonstrating promising and differentiated properties for further investigation in human trials. We look forward to working on this new collaboration with Biohaven, a world leader in the clinical development of CGRP-targeted therapies.”

Licensing 40

Licensing Licensing Production Development 40

Drug Channels

MARCH 15, 2022

Licenses for our DCI reports are regularly purchased by nearly every company involved in the drug channel: pharmaceutical manufacturers, wholesalers, pharmacists, pharmacy owners, hospitals, buyers, benefit managers, managed care executives, policy analysts, investors, consultants, and more.

Pharmacy 98

Pharmacy Drugs Marketing Containment 98

Pfizer

SEPTEMBER 28, 2022

COMIRNATY, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. Monovalent refers to any authorized and approved COVID-19 vaccine that contains or encodes the spike protein of only the Original SARS-CoV-2 virus . The information contained in this release is as of September 28, 2022.

Vaccination 101

Vaccination Vaccine Medicine Clinical Trials 101

The Pharma Data

JANUARY 4, 2021

Sanofi will be responsible for all future development, manufacturing and commercialization of IPH6101/SAR443579. We believe IPH6101/SAR443579 is the first NKp46-based NK cell engager to start development, demonstrating the next wave of scientific innovation at Innate. Eric Vivier, PhD, Chief Scientific Officer at Innate Pharma. “We

Development 40

Development Antibody Drugs Containment 40

FDA Law Blog

NOVEMBER 1, 2023

Gibbs — For more than three decades, FDA has claimed that the Federal Food, Drug & Cosmetic (FD&C Act) gives the agency legal authority to regulate laboratory developed tests (LDTs) as medical devices (see our prior post here ). Gaulkin & Jeffrey N.

In-Vitro 81

In-Vitro Regulation Manufacturing Licensing 81

Pfizer

JULY 8, 2022

Food and Drug Administration (FDA) approved the companies’ supplemental Biologics License Application (sBLA) for their COVID-19 vaccine, known as COMIRNATY® (COVID-19 Vaccine, mRNA), to include individuals 12 through 15 years of age. The information contained in this release is as of July 8, 2022. have completed a primary series.

FDA Approval 102

FDA Approval Vaccination Vaccine Clinical Trials 102

Druggist

NOVEMBER 6, 2020

Different brands of cough syrups contain very often the same active ingredients. Products containing just guaifenesin are available for self-selection in supermarkets, pharmacies and online. Combination products containing decongestants (pseudoephedrine) or a sedative antihistamine (diphenhydramine) are pharmacy-only medicines (P).

Medicine 69

Medicine Containment Production Pharmacy 69

Pfizer

JULY 19, 2022

The Pfizer-BioNTech COVID-19 Vaccine, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines.

Vaccination 100

Vaccination Vaccine Medicine Clinical Trials 100

Pfizer

FEBRUARY 16, 2023

The companies intend to work with regulatory authorities, and as previously announced, 1,2 aim for Pfizer to potentially submit a Biologics License Application (BLA) to the U.S. 2-4 About VLA15 VLA15 is the only Lyme disease vaccine candidate currently in clinical development. FDA in July 2017.

Clinical Trials 76

Clinical Trials Clinical Trials Vaccination Vaccine 76